The World Health Organization on Tuesday granted its endorsement of China’s second coronavirus vaccine.
According to the WHO, the vaccine made by Sinovac in China is more than 51% effective in preventing disease symptoms. It is 100% effective in preventing hospitalization and serious illness.
Clinical trials have included some adults over the age of 60, so the effectiveness in that age group cannot be assessed. However, the WHO refuses to set an age limit for the vaccine.
“There is no reason to believe that the vaccine has a different safety profile in the older and younger populations,” as released by a press release. “WHO recommends that countries using vaccines in older age groups undertake safety and efficacy monitoring to confirm the expected effect and contribute to making the recommendation stronger for all countries.
The move could lead to the vaccine in conjunction with the COVAX program, the WHO-led initiative to provide equal access to COVID-19 vaccines.
“The world desperately needs more COVID-19 vaccines to address the growing lack of access around the world,” said Mariângela Simão, WHO’s assistant director-general for access to the products. in health, said a statement.
WHO has approved seven coronavirus vaccines for the emergency use list, including another from China that is reported to be 79% effective in preventing disease symptoms and hospitalization.
Compared to other WHO -endorsed vaccines, both vaccines from China have limited public data. WHO experts have previously said that some quality data on the risk of serious side effects for the Sinovac vaccine lacking.
Copyright 2021 US News & World Report